PBM
MIRM icon

Propel Bio Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Propel Bio Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-70,000
Closed -$1.76M – 29
2024
Q1 		$1.76M Hold
70,000
– – 1.02% 18
2023
Q4 		$2.07M Buy
+70,000
New +$2.12M 1.71% 18

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Propel Bio Management's MIRM Position: Q2 2024 in Review

Propel Bio Management sold out of Mirum Pharmaceuticals (MIRM) in Q2 2024, closing a stake of 70,000 shares — an estimated $1.76M sold.

Propel Bio Management first reported a position in MIRM in Q4 2023 and held it in 2 quarters. The position peaked at $2.07M in Q4 2023. 160 funds tracked by Wall St. Rank hold MIRM as of Q2 2024.

  • Propel Bio Management reported no remaining Mirum Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Propel Bio Management sold 70,000 Mirum Pharmaceuticals shares in Q2 2024, an estimated $1.76M.
  • Propel Bio Management first reported a position in Mirum Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Propel Bio Management's Mirum Pharmaceuticals position peaked at $2.07M in Q4 2023.
  • 160 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2024.

Based on Propel Bio Management's 13F filing for Q2 2024, filed 12 Aug 2024.